Generic molecule: tofacitinib
Approval date: Nov. 6
The scoop: The approval of Pfizer's ($PFE) oral RA drug couldn't have come at a better time for the Big Pharma company, which has been struggling recently with its late-stage programs. Analysts projected that peak sales of the drug could reach $2 billion to $3 billion a year. A Pfizer spokesperson told Bloomberg that the drug will cost $2,055 a month, or a bit more than $24,000 a year.